Venkat Krishnamurthy

Venkat Krishnamurthy is a seasoned executive in the biotechnology sector, currently holding the position of SVP, Platform. He began his industry career at Dicerna Pharmaceuticals, where he was instrumental in developing the company’s siRNA platform and made significant contributions to the advancement of Nedosiran, a key program now in Phase 3. Following this, he served as a team lead at AstraZeneca in Boston, establishing a new modalities group that supported mRNA and genome editing projects from discovery through to clinical stages. Krishnamurthy also held an executive director role at Eli Lilly & Company, directing strategic initiatives for Lilly’s genetic medicine portfolio. His academic background includes a tenure as a faculty member at Harvard Medical School, where he led research on non-viral delivery systems for cell therapy and tissue engineering. Krishnamurthy has contributed to over 30 publications and patents, some of which have supported projects funded by the National Institutes of Health. He earned his doctorate in organic chemistry from the University of Illinois, Chicago, and completed postdoctoral training at Princeton University. Additionally, he holds bachelor’s and master’s degrees in chemistry from Loyola College and the Indian Institute of Technology, Chennai, respectively.